Neoleukin Therapeutics, Inc.
NLTX · NASDAQ
12/31/2024 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $66,223 | $28,162 | $265,293 | $730,733 |
| - Cash | $136,586 | $37,887 | $142,467 | $192,556 |
| + Debt | $12,428 | $12,070 | $12,984 | $12,122 |
| Enterprise Value | -$57,935 | $2,345 | $135,810 | $550,299 |
| Revenue | $0 | $0 | $6 | $451 |
| % Growth | – | -100% | -98.7% | – |
| Gross Profit | $0 | $0 | $6 | $451 |
| % Margin | – | – | 100% | 100% |
| EBITDA | -$82,605 | -$53,363 | -$60,698 | -$47,564 |
| % Margin | – | – | -1,011,633.3% | -10,546.3% |
| Net Income | -$75,144 | -$57,557 | -$60,692 | -$33,277 |
| % Margin | – | – | -1,011,533.3% | -7,378.5% |
| EPS Diluted | -3.96 | -5.07 | -5.5 | -3.2 |
| % Growth | 21.9% | 7.8% | -71.9% | – |
| Operating Cash Flow | -$70,603 | -$45,607 | -$47,558 | -$24,575 |
| Capital Expenditures | -$808 | -$1,110 | -$3,263 | -$2,219 |
| Free Cash Flow | -$71,411 | -$46,717 | -$50,821 | -$26,794 |